Strides Pharma Science Ltd Share Price

Pharmaceuticals

NSE: STAR Small Cap ISIN: INE939A01011

As on 18 November 2025 at 23:53 IST

₹947.45

-1.30

(-0.14%)

Sell Buy

Over 1 Month

18.74%

Over 6 Months

38.52%

Over 1 Year

58.47%

Over 3 Years

554.90%

Strides Pharma Science Ltd Summary

Close ₹948.75

Open ₹951

High ₹959

Low ₹939.15

Volume 2,11,022

Net Turnover (in Cr) ₹20.06

52Wk High ₹1,025

52Wk Low ₹513.05

52Wk High / Low

513.05

1,025

Strides Pharma Science Ltd Fundamentals

Key Financial Data

Market Cap (in Cr) ₹8,744.89

EPS (TTM) 8.30

Book Value (BV) 344.58

Div. Yield 0.42 %

P/E (TTM) 114.38

Price/Book Value 2.75

Delivery % 33.33 %

Face Value 10

Key Ratios

PE Ratio 2.14

PB Ratio 1.93

EV to Sales 3.43

PEG Ratio 0

ROA 64.89

ROE 85.90

Debt-Equity 0.43

Net Profit Margin 134.91

Operating Profit Margin 14.43

Strides Pharma Science Ltd Financials

Consolidated

Standalone

Yearly

Quarterly

Profit and Loss

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Revenue	4,624.06	3,929.83	3,778.72	3,202.24	3,367.30
Total Expenses	4,203.63	3,801.61	3,762.60	3,500.11	3,037.39
Profit Before Tax	486.92	-114.79	-286.20	-652.51	275.44
Profit After Tax	409.40	-143.90	-230.90	-474.25	243.79
Operating Profit After Depreciation	669.27	408.44	277.26	-121.13	479.97

Balance Sheet

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Fixed Assets	1,995.23	1,935.19	2,401.14	2,568.30	2,370.90
Total Non Current Assets	2,949.81	2,870.76	3,395.06	3,614.03	4,197.79
Total Current Assets	3,098.91	2,969	3,243.36	3,361.83	2,817.23
Total Assets	6,048.73	5,839.76	6,638.42	6,975.86	7,015.02
Total Shareholder's Fund	2,551.83	2,125.57	2,212.26	2,359.23	2,776.66

Cash Flow

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Net Cash From Operating Activities	684.37	701.07	44.41	-257.82	481.44
Net Cash Used In Investing Activities	-90.25	-150.22	302.28	-118.61	-522.04
Net Cash Used In Financing Activities	-642.58	-693.32	-213.92	421.32	-15.80

Profit and Loss

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Revenue	2,185.61	1,924.83	1,938.56	2,102.49	1,974.65
Total Expenses	2,107.50	1,942.40	1,988.32	2,080.98	1,863.02
Profit Before Tax	78.08	-22.93	-64.76	21.51	111.64
Profit After Tax	59.16	-24.27	4.68	180.19	78.24
Operating Profit After Depreciation	224.02	121.81	88.92	95.75	176.97

Balance Sheet

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Fixed Assets	795.96	771.89	623.89	629.36	605.97
Total Non Current Assets	2,885.44	3,490.70	3,493.34	3,458.61	3,477.48
Total Current Assets	2,145.50	2,411.18	2,126.40	1,975.25	1,743.86
Total Assets	5,030.94	5,901.87	5,619.74	5,433.86	5,221.33
Total Shareholder's Fund	3,192.74	3,527.60	3,455.05	3,406.68	3,248.06

Cash Flow

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Net Cash From Operating Activities	421.48	-14.01	241.74	-282.69	282.76
Net Cash Used In Investing Activities	-137.59	-68.69	-182.58	18.78	-275.64
Net Cash Used In Financing Activities	-370.32	93.34	10.82	250.73	-48.64

Particulars (in ₹ Cr.)	2025-09	2025-06	2025-03	2024-12	2024-09
Total Revenue	1,220.83	1,119.74	1,190.39	1,153.67	1,166.93
Total Expenses	990.32	901.66	972.53	943.36	982.99
Profit Before Tax	153.11	122.04	106.37	113.85	86.21
Profit After Tax	131.52	105.59	85.62	90.04	72.27
Operating Profit after Depreciation	257.65	226.76	232.97	216.88	212.35

Particulars (in ₹ Cr.)	2025-09	2025-06	2025-03	2024-12	2024-09
Total Revenue	522.15	498.62	555.96	550.92	519.55
Total Expenses	459.93	431.38	488.03	476.82	464.18
Profit Before Tax	25.39	16.41	28.32	21.38	16.38
Profit After Tax	32.04	13.35	16.13	14.94	17.26
Operating Profit after Depreciation	76.31	69	80.05	76.53	78.92

Strides Pharma Science Ltd Technicals

Support and Resistance

S3 S2 S1 Pivot R1 R2 R3

S1 938.93

S2 929.12

S3 919.08

Pivot 948.97

R1 958.78

R2 968.82

R3 978.63

Moving Average

20 SMA 891.12

50 SMA 867.04

100 SMA 871.87

200 SMA 778.80

Strides Pharma Science Ltd Corporate Actions

Strides Pharma Science Ltd

₹4.0/Share

Announcement Date 22 Jul 2025

Record Date 22 Jul 2025

Div Yield 40%

AGM Date: 03 Sep 2021

We wish to inform you that 30th Annual General Meeting ('AGM') of the Company will be held over video conference/ other audio-visual means on Friday, September 3, 2021 at 12:30 hrs IST in compliance with the circulars issued by the Ministry of Corporate Affairs ('MCA'), Government of India and Securities and Exchange Board of India ('SEBI') and all other applicable laws. As informed by the Company on May 27, 2021, Board of Directors has recommended a final dividend of Rs. 2.50 per share. The Record Date for the purpose of Final Dividend for FY 2020-2021 will be Friday, August 6, 2021. Final Dividend once approved by the Members in the ensuing AGM will be paid within 30 days from the date of approval. Newspaper advertisement titled 'Intimation about 30th Annual General Meeting of the Company & Record Date for Final Dividend' (As per BSE Announcement Dated on 27/7/2021) We wish to inform you that the 30th AGM of the Company was held on Friday September 3 2021 through Video Conference. Pursuant to Regulation 30 Part A of Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 please find enclosed the summary of proceedings of the AGM. This is for your information and records.(As Per BSE Announcement Dated on 9/3/2021 8:10:05 AM) We wish to inform you that the 30th Annual General Meeting (AGM) of the Company was held on Friday September 3 2021. All the items of the business as mentioned in the AGM Notice dated May 27 2021 have been transacted and all the resolutions have been passed by the Members with requisite majority by way of remote e-voting and e-voting at the meeting. In this connection please find enclosed the following: a) Voting Results as required under Regulation 44 of SEBI Listing Regulations as Annexure 1. b) Report of Scrutinizer dated September 4 2021 pursuant to the Companies Act 2013 and Rules made thereunder as Annexure 2. This is for your information and records. (As Per BSE Announcement Dated on 9/4/2021 7:54:24 AM) We wish to inform you that the 30th AGM of the Company was held on Friday, September 3, 2021 through Video Conference. Pursuant to Regulation 30, Part A of Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, please find enclosed the summary of proceedings of the AGM. This is for your information and records. (As Per BSE Announcement Dated 03.09.2021)

AGM Date: 09 Sep 2022

AGM 09/09/2022 This is to inform you that the 31st Annual General Meeting (AGM) of the Company is scheduled to be held on Friday, September 9, 2022, at 12:30 hrs IST through Video Conference/ Other Audio-Visual Means. As required under SEBI Listing Regulations, we are enclosing herewith Notice of the AGM and Annual Report for FY 2021-22 which is being sent through electronic mode to the Members of the Company. A copy of the same is also available on the Company's website www.strides.com This is for your information and records. (As Per BSE Announcement Dated on 18.08.2022) We wish to inform you that the 31st AGM of the Company was held on Friday, September 9, 2022 through Video Conference. Pursuant to Regulation 30, Part A of Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, please find enclosed the summary of proceedings of the AGM. This is for your information and records. (As Per BSE Announcement dated on 09.09.2022) Outcome of the 31st Annual General Meeting of the Company Strides Pharma Science Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. (As Per BSE Announcement Dated on 10.09.2022)

AGM Date: 28 Aug 2023

Newspaper advertisement titled - Intimation about 32nd Annual General Meeting of the Company and Record Date for Dividend. Newspaper Publication title ''Notice of 32nd Annual General Meeting, Remote E-Voting and Cut-Off Date'' (As Per BSE Announcement Dated on 05.08.2023) Outcome of the 32nd Annual General Meeting of Strides Pharma Science Limited - Disclosure under SEBI Listing Regulations Outcome of the 32nd Annual General Meeting of Strides Pharma Science Limited - Disclosure under SEBI Listing Regulations (As Per BSE Announcement Dated on 30.08.2023)

AGM Date: 25 Sep 2024

AGM 25/09/2024 Annual Report for FY24 (As Per BSE Announcement Dated on: 02/09/2024) Announcement of Proceedings of the 33rd Annual General Meeting of the Company. (As Per BSE Announcement Dated on 25.09.2024) Scrutinizers report for Strides 33rd Annual General Meeting. (As Per Bse Announcement Dated on 26.09.2024)

AGM Date: 07 Aug 2025

Intimation to members about Annual General Meeting of the Company and Record date for the purpose of Final Dividend for FY25 Notice of 34th Annual General Meeting (As Per BSE Announcement Dated on :11.07.2025) Proceedings of 34th Annual General Meeting of the Company (As Per BSE Announcement Dated on:07.08.2025) Intimation regarding Voting Results and Scrutinizer Report of 34th Annual General Meeting of the Company (As Per BSE Announcement Dated on:08.08.2025)

EGM Date: 30 Mar 2022

Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') Intimation regarding rescheduling of Extraordinary General Meeting (As Per BSE Announcement Dated on 17.02.2022)

EGM Date: 07 Apr 2022

EGM 07/04/2022 Update on Proposed Preferential Issue We wish to inform you that the EGM of the Company was held on Thursday, April 7, 2022 through Video Conference. Pursuant to Regulation 30, Part A of Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, please find enclosed the summary of proceedings of the EGM. This is for your information and records. We wish to inform you that the EGM of the Company was held on Thursday, April 7, 2022 through Video Conference. Pursuant to Regulation 30, Part A of Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, please find enclosed the revised summary of proceedings of the EGM. This is for your information and records. (As Per BSE Announcement Dated 07.04.2022) Outcome of the Extraordinary General Meeting of the Company (As per BSE Announcement Dated on 9/4/2022) Strides Pharma Science Ltd has informed BSE regarding the details of Voting results of EGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here (As Per BSE Announcement Dated 11.04.2022)

EGM Date: 06 Feb 2023

EGM 06/02/2023 Notice of Extraordinary General Meeting of the shareholders of the Company scheduled to be held on February 6, 2023 at 12:30 hrs IST through Video Conference/ Other Audio-Visual Means. (As Per BSE Bulletin Dated on 13.01.2023) We wish to inform you that EGM of the Company was held on Monday, February 6, 2023 through Video Conference. Pursuant to Regulation 30, Part A of Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, please find enclosed the summary of proceedings of EGM. Outcome of the Extraordinary General Meeting of the Company held on February 6, 2023 (As Per BSE Announcement Dated on 06.02.2023)

EGM Date: 10 Sep 2024

COM 10/09/2024 Outcome of NCLT Convened meeting - Approval from Equity shareholders and Secured Creditors for creation of OneSource - India''s first Specialty Pharma CDMO (As Per BSE Announcement dated on 11.09.2024)

Strides Pharma Science Ltd Peer Comparison

Company	Price	Market Cap (in Cr)
Sun Pharmaceutical Industries Ltd	₹1,763.70	₹4,23,170.71
Divis Laboratories Ltd	₹6,523.25	₹1,73,171.79
Torrent Pharmaceuticals Ltd	₹3,816.75	₹1,29,170.36
Cipla Ltd	₹1,536.25	₹1,24,093.85
Dr Reddys Laboratories Ltd	₹1,244.50	₹1,03,868.61

Strides Pharma Science Ltd Top Mutal Funds Invested

Fund Name	AUM
Quant Business Cycle Fund	1.74%
Quant Multi Cap Fund	1.43%
JM Small Cap Fund	1.15%
WhiteOak Capital Pharma and Healthcare Fund	1.10%
Quant Small Cap Fund	1.02%

Strides Pharma Science Ltd News

Strides Pharma soars after Q2 PAT climbs 82% YoY to Rs 131 cr

Strides Pharma Science surged 13.77% to Rs 967 after the company's consolidated net profit jumped 81.98% to Rs 131.52 crore on 4.62% increase in revenue from operations to Rs 1220.83 crore in Q2 Sept 2025 over Q2 Sept 2024.

31 Oct 2025, 02:21 pm

Strides Pharma Science announces board meeting date

On 31 October 2025

25 Oct 2025, 11:04 am

Strides Pharma arm partners with Kenox Pharma for nasal spray development

Strides Pharma Science announced that its wholly owned subsidiary, Strides Pharma Global Pte, Singapore, has entered into a strategic product development partnership with Kenox Pharmaceuticals Inc.

09 Sep 2025, 11:01 am

Strides Pharma Science to announce Quarterly Result

On 29 July 2025

24 Jul 2025, 10:23 am

Strides Pharma Science schedules AGM

On 7 August 2025

10 Jul 2025, 10:16 am

Strides Pharma Science Ltd Stock Analysis

Annual revenue for Strides Pharma Science Ltd increased by 13.55% to ₹2,185.61 crore in FY 2025 from ₹1,924.83 crore in FY 2024.
Annual Net Profit for Strides Pharma Science Ltd decreased by 343.69% to ₹59.16 crore in FY 2025 from ₹-24.27 crore in FY 2024.
Promoter Shareholding in Strides Pharma Science Ltd decreased by 1.53% in the most recent quarter, from 28.30% in June 2025 to 27.86% in September 2025.
Strides Pharma Science Ltd delivered a 1-year return of 58.47% compared to the Nifty 50, which provided a return of 10.91% as of the last trading session.
Strides Pharma Science Ltd share price moved down by 0.14% from its previous close of INR ₹948.75. The latest Strides Pharma Science Ltd share price is INR ₹947.45.
Strides Pharma Science Ltd share price today has been at a low of 939.15 and a high of 958. Over the past 52 weeks, the Strides Pharma Science Ltd share price has seen a low of 513.05 and a high of 1,025.